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Heparin is frequently prescribed for the prevention and treatment of 
thromboembolic disease.[1] Heparin-induced thrombocytopenia (HIT) 
is an immune-mediated complication of heparin therapy associated 
with thrombocytopenia and an increased risk of venous and/or arterial 
thrombosis, which may be limb- and/or life-threatening.[2] Since 
heparin is widely used, a high level of awareness of HIT is important. 
Although rare, HIT is particularly relevant in the current era of 
COVID-19, when most COVID-19 inpatients receive heparin therapy 
as thromboprophylaxis.[3] There are important similarities between 
HIT and vaccine-induced immune thrombotic thrombocytopenia 
(VITT), including similar pathophysiology involving platelet factor 4 
(PF4), increased thrombotic risk and thrombocytopenia.[4]
HIT is caused by immunoglobulin G (IgG) autoantibodies that 
develop in response to heparin exposure. These IgG autoantibodies are 
directed against PF4/heparin complexes, leading to immune complex 
formation and subsequent platelet activation. The coagulation cascade 
is then activated, leading to widespread clot formation.[2,5] Recognition 
of HIT is critical to prevent and appropriately manage HIT-associated 
complications.[2]
This review includes a short discussion on the pharmacology of 
heparin and the pathogenesis of HIT, with reference to the recent 
literature. Guidance on the clinical features, laboratory testing 
and clinical management of HIT is provided. Key similarities and 
differences between HIT and VITT are discussed.
Heparin
Pharmacology
Heparin is a mixture of negatively charged oligo- and polysaccharides 
that belong to the glycosaminoglycan (GAG) family of molecules. 
The GAG family of molecules includes endogenous heparin-like 
molecules expressed on endothelial cells.[6] Heparin is isolated 
from porcine intestinal mucosa and is purified and processed 
prior to pharmaceutical use.[6,7] Heparin functions primarily by 
potentiating the anticoagulant action of antithrombin (AT) several 
thousand-fold, which inhibits activated thrombin (activated 
factor  II).[8] Fig.  1 demonstrates the pharmacological action of 
heparin and its primary interaction with AT.
Heparin formulations
The two major heparins in clinical practice are unfractionated 
heparin (UFH) and low-molecular-weight heparin (LMWH). Table 1 
summarises the key differences between UFH and LMWH.
UFH is comprised of a heterogeneous mixture of oligo- and 
polysaccharide chains. This structural heterogeneity results 
in unpredictable bioactivity and physiological effects, which 
mandates regular laboratory monitoring. UFH also interacts with 
numerous proteins and cells in vivo, resulting in certain off-target 
effects (Table  1). [1,12] LMWH is a derivative of UFH resulting 
from the controlled depolymerisation of UFH polysaccharide 
chains. Depolymerisation of UFH results in heparin fragments 
of shorter length and therefore lower molecular weight.[7,12,13] The 
various manufacturing techniques employed by pharmaceutical 
manufacturers result in LMWH of different molecular weights and 
pharmacological properties. The ratio of anti-factor Xa to anti-factor 
IIa therefore differs slightly between different LMWH products.[1,13] 
The pentasaccharide unit of heparin is the shortest portion of the 
heparin molecule able to bind and activate AT. This pentasaccharide 
unit facilitates the inhibition of activated factor X only. A longer 
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heparin chain (~18 saccharide sequences) is 
required for AT to exert its inhibitory effect 
on thrombin (activated factor II).[7]
LMWH is now more widely used than 
UFH owing to its ease of administration, 
more predictable pharmacological effects, 
improved side-effect profile and equivalence 
in efficacy and safety.[1,13] However, owing 
to its rapid onset of action and reversibility, 




Two types of HIT have been described, 
which differ in their underlying pathogenesis 
and clinical significance (Table 2).
Pathophysiology of HIT
Platelets have a lifespan of 7 - 10 days and 
play  an essential role in primary haemo-
stasis. [14] Platelets store haemostatic media-
tors within their granules, including PF4, 
which is a positively charged protein released 
upon platelet activation. Thereafter PF4 
readily binds negatively charged endogenous 
heparin-like molecules present on endo-
thelial cells and high-molecular-weight 
fragments of heparin. Because PF4 has a high 
affinity for heparin, circulating PF4/heparin 
complexes readily form in the circulation. [2] 
These PF4/heparin complexes can be 
immunogenic and result in IgG antibody 
formation, which occurs more commonly 
with UFH than LMWH use. The anti-PF4/
heparin IgG antibodies bind to PF4/heparin 
complexes within the circulation, leading 
to platelet, monocyte, endothelial cell and 
neutrophil activation. These interactions 
lead to subsequent profound activation of 
coagulation and thrombus formation.[2,5,15] 
Fig. 2 demonstrates the pathogenesis of 
clinically significant HIT.
Not all circulating PF4/heparin antibodies 
can activate platelets. The iceberg model of 
HIT (Fig. 3) explains the relationship between 
the higher frequency of PF4/heparin anti-
body detection in immunoassays (see the 
section on laboratory diagnosis of HIT) 
and the much lower prevalence of clinically 
significant HIT.[16]
Prevalence and clinical 
manifestations of HIT
Prevalence
The prevalence of HIT is reported as up to 
2.7%,[17] depending on the type and dose of 
heparin used (UFH v. LMWH), previous 
heparin exposure, the clinical circumstances 
and duration of therapy.[2,17] Rarely, HIT 
may also occur without previous heparin 
exposure, so-called spontaneous HIT. [2] 
Clinical conditions associated with the 
release of PF4 such as post-surgery, trauma 
or sepsis are associated with an increased 
risk of HIT.[2,18] Table 3 summarises the 
prevalence of HIT reported in the literature 
for different clinical scenarios.
Clinical manifestations
Thrombocytopenia in temporal association 
with heparin is noted in up to 95% of patients 
diagnosed with HIT. Classically the platelet 
count decreases by 30 - 50% from baseline, 
which results in moderate thrombocytopenia 
(nadir platelet count 50 - 70 × 109/L).[2] 
However, if the baseline platelet count is 
high, the platelet count may drop by 50% but 
still be within the normal range. The nadir 
in platelet count typically occurs within 5 - 
10 days after commencing heparin therapy. 
Thrombocytopenia can occur within 24 
hours if heparin exposure occurred within 
the preceding 100 days, and where the 
patient still has circulating anti-PF4/heparin 
antibodies.[2,18] Post cardiopulmonary bypass 
surgery, a drop in platelet count is common 
within the first 72 hours after surgery, which 
is multifactorial; however, platelet count 
recovery postoperatively followed by a 
subsequent drop in platelet count 5 - 10 days 
after heparin exposure is highly suspicious of 
HIT.[18] In view of the difficulty of evaluation 
for HIT post cardiac surgery, a scoring 
system specifically for this situation has been 
proposed.[21]
Approximately 50% of patients who 
develop clinically significant HIT also develop 
thrombosis.[13] HIT-associated thrombosis 
can affect any vascular bed including venous 
and arterial. The venous system, particularly 
at vascular catheter sites, is most commonly 
affected. Venous limb gangrene, skin necrosis 
and bilateral adrenal haemorrhage may 
occur as a result of widespread thrombosis. 
The severity of thrombocytopenia inversely 
correlates with thrombotic risk.[2] Bleeding 
resulting from HIT is extremely rare.[18]
Upon diagnosis of HIT, immediate cessa-
tion of heparin and prompt anticoagulation 
with an alternative agent should ensue, since 
patients are profoundly prothrombotic. After 
cessation of heparin, up to 65% of patients 
will recover their platelet counts to baseline 
levels within 7 days.[2] The prothrombotic 
phase of HIT continues until the platelet 
count has returned to baseline.[21]
4Ts clinical probability scoring 
system
If a patient is receiving heparin therapy 
and HIT is suspected, the probability of 
HIT should be determined using the 4Ts 
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Fig. 1. The interaction between heparin and AT within the coagulation cascade. AT is a serine protease 
inhibitor and major natural anticoagulant. Heparin binding to AT activates it into a potent inhibitor of 
thrombin (activated factor II) and activated factor X.[8] (AT = antithrombin; TF = tissue factor; FVIIa = 
activated factor VII; Factor Xa = activated factor X; Factor Va = activated factor V.)
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clinical probability scoring system.[18,21] The 4Ts score provides 
information on the likelihood of HIT and guides acute management 
and laboratory testing. Lo et al.[19] first introduced and validated 
the 4Ts scoring system for HIT in 2003. Four typical features (the 
‘4Ts’) are incorporated and the likelihood of HIT is estimated based 
on the cumulative score (Table 4).[19] The scoring system has an 
excellent negative predictive value if a low probability score of 0 - 3 
is calculated (>0.98).[22] This means that a negative screening result is 
very helpful to exclude HIT.
Monitoring of platelet counts to  
screen for HIT
The British Committee for Standards in Haematology (BCSH) 
recommends monitoring platelet counts in select patients receiving 
heparin therapy. These recommendations have been adapted and 
are presented in Table 5. In addition, recommendations from local 
experts on platelet count monitoring in patients receiving LMWH, 
or hospitalised with COVID-19 and receiving heparin therapy, are 
presented.
Laboratory diagnosis of HIT
The laboratory tests used for the screening and/or diagnosis of 
HIT can be divided into two main groups. The first group are 
immunoassays used to screen for anti-PF4/heparin antibodies. These 
immunoassays are used as an initial screening step in patients with 
an intermediate to high 4Ts score.[2] For most patients with a high 4Ts 
score (score of 6 - 8), the presence of a positive HIT immunoassay 
confirms the diagnosis of HIT without the need for confirmatory 
testing with a functional HIT assay.[2,21] Screening for anti-PF4/
heparin antibodies is offered by two public sector laboratories in 
South Africa (SA), namely the National Health Laboratory Service 
(NHLS) at Groote Schuur Hospital in Cape Town and the Special 
Haemostasis Laboratory at Universitas Hospital in Bloemfontein. 
Ampath Laboratories offers an enzyme-linked immunosorbent assay 
(ELISA) screening test. For patients with an intermediate 4Ts score 
(score of 4 - 5), further functional testing is required to confirm the 
functional activity of the anti-PF4/heparin antibodies detected.[1,18] 
This is due to the high rate of asymptomatic seroconversion seen in 
patients exposed to heparin. Up to 50% of patients develop anti-PF4/
heparin antibodies (particularly in cardiac bypass surgery), whereas 
only 0.2 - 5% will develop clinically significant complications.[2,16]
The functional assays for HIT are platelet activation assays 
that assess platelet activation in the presence of anti-PF4/heparin 
antibodies and heparin. These are technically difficult tests and 
not routinely performed.[2,23] Currently, the Special Haemostasis 
Laboratory at Universitas Hospital is the only laboratory offering 
functional HIT testing nationally. The heparin-induced platelet 
aggregation assay (HIPA) offers high specificity (>95%) and a high 
positive predictive value (89 - 100%) for HIT.[2,23] The HIPA assay 
indirectly assesses the ability of the anti-PF4/heparin antibodies to 
Table 1. Comparison between UFH and LMWH[9,10]
Features UFH LMWH
Source Porcine intestinal mucosa Fractionated from UFH
Molecular weight 3 000 - 15 000 daltons 3 000 - 5 000 daltons
Half-life 45 - 60 minutes 240 minutes
Administration Continuous intravenous infusion Subcutaneous administration
Pharmacokinetics The heterogeneity of polysaccharide chains 
affects drug potency and clearance between 
individuals
More homogeneous polysaccharide chains than UFH
• <50% bioavailability • 90% bioavailability
• Complex mixed-order kinetics due to 
variable interaction with endogenous 
proteins and endothelial cells
• Shows first-order kinetics with a clear dose-response 
relationship
• Clearance via the RES (renal clearance is 
dose dependent and saturable)
• Renal clearance (not dose dependent, non-saturable 
and linear)
Monitoring Routine monitoring with aPTT; ACT in high-
dose UFH
Generally not required (with exceptions*)
Molecular targets Anti-factor Xa and anti-factor IIa activity in a 
1:1 ratio
Preferentially binds and inactivates factor Xa with  
a 2 - 5:1 anti-factor Xa to anti-factor IIa ratio
Reversal Protamine sulphate† Partial reversal with protamine sulphate†
Major side-effects • Bleeding • Bleeding
• HIT in ~2.7%‡ • HIT and osteoporosis (<1% of cases)
• Cutaneous hypersensitivity reaction if given 
s.c. in ~7.5%
• Cutaneous hypersensitivity reaction in ~7.5%
• Osteoporosis in ~2%§
UFH = unfractionated heparin; LMWH = low-molecular-weight heparin; RES = reticulo-endothelial system; aPTT = activated partial thromboplastin time; ACT = activated clotting time;  
HIT = heparin-induced thrombocytopenia; s.c. = subcutaneous.
*LMWH levels should be monitored using a specific anti-Xa assay performed 3 - 4 hours post dose in the following clinical scenarios: (i) renal impairment (creatinine clearance <30 mL/min);  
(ii) paediatrics; (iii) to assess compliance; and (iv) to assess adequate dosing. For these clinical scenarios, anti-Xa testing is required after each dose adjustment and until the desired anti-Xa 
activity is achieved.[1]
†1 mg protamine sulphate neutralises 100 U of heparin; however, the dose of protamine should not exceed 50 mg.[11]
‡The prevalence of HIT differs depending on the clinical scenario, and the dose and/or duration of UFH.[10]
§Heparin-induced osteoporosis is a complication of long-term heparin use for >1 month.[1,10]
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cause platelet activation and aggregation in 
the presence of heparin.[23] All public sector 
HIT tests should be discussed with either 
the NHLS Universitas Special Haemostasis 
Laboratory at +2751 405 3040 or the NHLS 
Groote Schuur Haematology Laboratory at 
+2721 404 3191 for testing recommendations 
and sample requirements.
Owing to the high prevalence of 
asymptomatic seroconversion with heparin 
exposure (presence of anti-PF4/heparin 
antibodies without thrombocytopenia or 
other clinical complications), laboratory 
testing in a patient with a low 4Ts probability 
score is not indicated.[2,18,21] Laboratory 
testing for HIT should not be performed 
in patients with a low 4Ts score. Fig. 4 
provides an algorithm for HIT testing and 
Table 5 a summary of the laboratory testing 
recommendations.
Laboratory error or differences in antibody 
specificity can rarely result in a false-negative 
immunoassay. Clinical re-evaluation and 
repeat HIT testing, including a functional 
assay, is therefore indicated in cases where 
the clinical suspicion for HIT remains 
high. [21]
HIT and COVID-19
The World Health Organization declared 
SARS-CoV-2 a pandemic in March 2020. By 
the end of June 2021, the number of SARS-
CoV-2 infections exceeded 178 118 597 
confirmed cases worldwide, with >3 864 180 
deaths reported.[25] SARS-CoV-2  causes 
COVID-19, which in severe cases results 
in immune dysregulation with acute respir-
atory distress syndrome, multiorgan dys-
function, and thromboembolism  due to 
the activation of the coagulation system 
and endothelium.[26,27] Haemostatic abnor-
malities may occur, resulting in a hyper-
coagulable state often complicated by 
venous thrombosis, pulmonary embolism 
or stroke.[3,27] Guidelines support heparin 
therapy, typically LMWH, for the prevention 
and treatment of thromboembolic disease 
in COVID-19[28,29] because of its anti-
inflammatory properties,[9] efficacy, large 
body of clinical experience, availability of 
laboratory monitoring, and predictable 
pharmacokinetics.
Although both COVID-19 and HIT 
are hypercoagulable disorders with a 
significant risk of thrombotic complica-
tions, management differs markedly. In 
COVID-19, heparin is the mainstay of 
thromboprophylaxis and therapy, whereas 
immediate discontinuation of heparin is 
absolutely essential in the management of 
HIT.[2,3] Patients with severe COVID-19 may 
receive heparin for prolonged periods of 
time (commonly >5 days), which increases 
their risk of developing HIT. An increased 
frequency of anti-PF4/heparin antibodies 
has been reported in severe COVID-19. [3,24] 
However, the true prevalence of HIT in 
COVID-19 remains uncertain.[3]
Table 2. Classification of heparin-induced thrombocytopenia[2]
Features Cause of thrombocytopenia Clinical effect
Type I Heparin-induced platelet agglutination Clinically insignificant transient, mild thrombocytopenia 
≤3 days of heparin therapy
Platelet count ≥100 × 109/L
Type II* Immune-mediated† Serious with potential limb- or life-threatening 
complications‡
Platelet count nadir typically  50 - 70 × 109/L
*Clinically significant.
†Anti-platelet factor 4/heparin antibodies develop in 8 - 50% of patients exposed to heparin therapy, but only 0.2 - 5% develop clinical complications.[2]






















Fig. 2. Pathogenesis of clinically significant heparin-induced thrombocytopenia.[2,5] Plasma cells 
produce and secrete specific IgG antibodies in response to circulating PF4/heparin complexes. The 
antibody/PF4/heparin immune complexes then bind platelets, monocytes and neutrophils via their 
Fcγ receptors, resulting in platelet and immune system activation. Procoagulant mediators such as 
TF-rich microparticles are released, and NETosis occurs. NETosis due to neutrophil extracellular trap 
formation, and the release of TF-rich microparticles result in activation of the coagulation cascade and 
thrombin formation. Thrombin, a potent activator of platelets, monocytes and endothelial cells, further 
potentiates their activation and TF production. Widespread activation of the coagulation cascade 
results in thrombus formation in numerous organ systems and tissues, resulting in ischaemia and 
localised necrosis. The activation and incorporation of platelets within the thrombi, as well as increased 
peripheral sequestration by the spleen, result in thrombocytopenia. (IgG = immunoglobulin G; PF4 = 
platelet factor 4; TF = tissue factor; MPs = microparticles; GAGs = glycosaminoglycans.)
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Clinical distinction between severe 
COVID-19 and HIT is often challenging. 
Thrombotic complications (thrombosis at 
venous, arterial and unusual sites) occur 
in ~50% of severe COVID-19 and 50% 
of clinically significant HIT. Venous 
thromboses are more frequent than arterial 
thromboses in both COVID-19 and HIT. 
Thrombocytopenia and disseminated intra-
vascular coagulation (DIC) may occur 
in severe fatal COVID-19, and moderate 
thrombocytopenia is found in HIT.[3]
Until further information is available 
regarding the true prevalence of HIT 
in COVID-19, we recommend baseline 
platelet counts and alternate-day platelet 
count monitoring for hospitalised 
COVID-19 patients receiving any form 
of heparin therapy (UFH or LMWH; 
prophylactic, intermediate or therapeutic 
dosing; dialysis catheter flushing). 
Additionally, HIT testing should be 
performed if HIT is suspected and the 




In the wake of large-scale SARS-CoV-2 
vaccine roll-outs, a novel syndrome 
characterised by thrombosis (often at 
unusual sites) and thrombocytopenia has 
been described. This syndrome, named 
VITT, typically develops 5 - 24 days after 
vaccination with an adenoviral vector 
vaccine. The two currently available adeno-
viral vector vaccines are ChAdOx1 nCoV-
19 vaccine (AstraZeneca)[30-32] and Ad26.
COV2.S vaccine (Johnson & Johnson/
Janssen).[33] At the time of writing (June 
2021), the Ad26.COV2.S had been admini-
stered to 490 000 South Africans as part 
of the Sisonke Trial. Data published on 
the first 288 000 participants revealed 
no cases of VITT. [34] The underlying 
pathophysiological mech anisms that lead 
to VITT remain to be clarified.
The pathological findings in VITT and 
HIT are similar. In both conditions, patients 
develop high levels of antibodies to PF4 as 
identified by the PF4 antibody ELISA test. 
In contrast to HIT, in VITT the binding 
of antibodies to PF4 and activation of 
platelets occur in the absence of heparin.[35] 
Another difference between HIT and VITT 
is that the platelet nadir tends to be much 
lower in VITT compared with HIT. A high 
frequency of decompensated DIC has also 
been reported in patients with VITT.[4]
An adapted 4Ts scoring system has been 
proposed to predict the pretest probability of 
VITT. Laboratory testing is recommended 
in individuals with an intermediate or high 
score.[4] Current national and international 
guidelines recommend that the diagnosis 
of VITT is confirmed with an approved 
PF4 antibody ELISA test and that the 
rapid immunoassays used to detect HIT 
should not be used unless they have been 
specifically validated for the diagnosis/
exclusion of VITT.[35,36]
The management of VITT is similar to 
that of HIT (see below) with the addition 
of high-dose intravenous immunoglobulin. 
A second dose of the culprit vaccine, if 
required, should be avoided.[36]
Management of HIT
The BCSH and the American Society 
of Hematology (ASH) have provided 
guidelines for the management of HIT.[18,21] 
The diagnosis and management of HIT 
should occur in consultation with a clinical 
haematologist experienced in managing 
HIT.
In patients with suspected HIT 
(intermediate or high 4Ts score), while 
awaiting HIT laboratory test results (Fig. 
4), heparin therapy should immediately 
cease and an alternative anticoagulant 
should be started. Data on the comparative 
safety and efficacy of the various non-
heparin anticoagulants is unclear owing to 
Table 3. The prevalence of clinically significant HIT for different patient groups[2,17,19,20]
Variable Prevalence of clinically significant HIT
LMWH v. UFH, prophylactic doses 0% v. 2.7% (p=0.0018)[17]
LMWH v. UFH, therapeutic doses 1.2% v. 1.5% (p=0.246)[20]
Clinical groups Higher prevalence in surgical v. non-surgical patients; females v. males; 
adult v. paediatric patients
Date of last heparin exposure Higher prevalence if heparin was used within the previous 100 days
Duration of heparin exposure Highest prevalence after 5 - 10 days of consecutive heparin therapy




Patient exposed to heparin
Fig. 3. Iceberg model for heparin-induced thrombocytopenia.[16] (PF4 = platelet factor 4.)
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a lack of adequate randomised controlled trials. [37] The choice of 
alternative anticoagulant will depend on clinician experience, drug 
availability, cost, expected drug-drug interactions, availability of 
laboratory testing for drug monitoring, patient age, organ function, 
weight, comorbidities and bleeding risk, as well as other established 
factors. [21] For most clinically stable patients without an excessive 
bleeding risk, fondaparinux or direct oral anticoagulants (DOACs) 
such as rivaroxaban are reasonable choices for the initial treatment 
of acute HIT.[21]
Currently, the BCSH and ASH guidelines recommend that the 
alternative anticoagulant be started at therapeutic dose (or dose-
adjusted according to weight, creatinine clearance and/or liver 
function as per pharmaceutical guidelines).[18,21]
The duration of anticoagulant therapy for patients with confirmed 
HIT depends on the initial indication for heparin therapy (prophylaxis 
v. treatment of thromboembolic disease), and whether there is 
HIT without thrombosis (so-called ‘isolated HIT’) or HIT with 
thrombosis. In patients with confirmed HIT without thrombosis, 
Table 4. The 4Ts clinical probability scoring system for heparin-induced thrombocytopenia[19]*
4Ts 2 points 1 point 0 points
Thrombocytopenia >50% drop and platelet nadir  
≥20 × 109/L
30 - 50% drop or platelet  
nadir 10 - 19 × 109/L
<30% drop or platelet  
nadir <10 × 109/L
Timing of platelet count fall Clear onset 5 - 10 days after heparin 
exposure or platelet fall ≤1 day (prior 
heparin exposure within 30 days)
Onset after day 10 or platelet fall 
<1 day (prior heparin exposure in 
preceding 30 - 100 days)
<4 days with no prior 
heparin exposure
Thrombosis† Confirmed new thrombosis‡ Progressive or recurrent 
thrombosis or possible new 
(unconfirmed) thrombosis
None
Other cause for 
thrombocytopenia favoured
No Possible Likely
High probability: 6 - 8; Intermediate probability: 4 - 5; Low probability: 0 - 3
DVT = deep-vein thrombosis; UFH = unfractionated heparin.
*Reproduced from Lo et al.,[19] with permission from John Wiley & Sons.
†The American Society of Hematology 2018 guidelines[21] recommend bilateral lower-limb compression ultrasonography to exclude asymptomatic proximal DVT. Upper-limb ultrasonography is 
suggested in those with an indwelling central venous catheter to exclude asymptomatic DVT.[21]
‡Patients with skin necrosis at the heparin injection site or acute systemic reaction after UFH bolus score 2 points even in the absence of confirmed thrombosis.[17]
Table 5. Recommendations for the diagnosis and management of HIT
Platelet monitoring
• A baseline platelet count should be performed prior to starting heparin therapy.*
• If heparin exposure occurred during the preceding 100 days, monitoring of the platelet count should commence on day 0 of heparin 
exposure and repeated at 24 hours. Monitoring is recommended until heparin is stopped.*
• For patients receiving UFH, alternate-day platelet counts should be performed from days 4 to 14 or until heparin is stopped.*
• For patients receiving therapeutic-dose LMWH, platelet counts should ideally be performed every 5 days from days 4 to 14 or until heparin 
is stopped.†
• For medical patients receiving prophylactic-dose LMWH, platelet counts should ideally be performed once a month until heparin is stopped.†
• For obstetric patients receiving prophylactic-dose LMWH, platelet counts should ideally be performed once a month, or at least once a trimester.†
• For hospitalised COVID-19 patients receiving any form of heparin, alternate-day platelet counts should be performed from days 4 to 14 or 
until heparin is stopped.‡
Clinical diagnosis of HIT
• The 4Ts score should be used to determine the pretest probability of HIT (Table 4).
Laboratory diagnosis of HIT§
• HIT testing should be performed in all patients with an intermediate/high pretest probability 4Ts score.
• HIT testing is not recommended for patients with a low 4Ts score.
• The diagnosis of HIT can be made with a high 4Ts score and positive HIT immunoassay antibody testing.
• The diagnosis of HIT can be made with an intermediate 4Ts score, positive HIT antibody and functional assay.
Management of HIT
• In patients with an intermediate or high 4T score (while awaiting the HIT test results), heparin should be stopped, and an alternative 
anticoagulant started at therapeutic doses.
• Warfarin therapy should be avoided in the acute phase of HIT and until the platelet count has recovered.
• Contraindications to and dose adjustments of alternative anticoagulants should be followed as for non-HIT VTE.
• Alternative anticoagulants include fondaparinux (subcutaneous), rivaroxaban (oral) or argatroban (intravenous).
• Platelet transfusions should be avoided.
HIT = heparin-induced thrombocytopenia; UFH = unfractionated heparin; LMWH = low-molecular-weight heparin; VTE = venous thromboembolism.
*Based on British Committee for Standards in Haematology recommendations (all graded 2C).[18]
†Recommendations based on local expert opinion and consensus agreement.
‡Recommendation based on the higher frequency of anti-PF4/heparin antibodies detected in severe COVID-19; however, the true prevalence of HIT in this patient group is currently uncertain.[3,24]
§HIT testing is indicated if uncertainty about the correct 4Ts score exists. 
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anticoagulation should continue for at least 
4 weeks and until the platelet count has 
recovered (platelet count >150 × 109/L). In 
patients with HIT-associated thrombosis 
(including those with asymptomatic 
thrombosis), the patient should be treated 
as per thrombosis therapeutic guidelines 




Fondaparinux, a synthetic pentasaccharide 
heparin, exerts its anticoagulant effect via 
the selective binding of AT. It is structurally 
similar to LMWH and could trigger anti-
PF4/heparin antibody formation and release. 
In contrast to other heparins, fondaparinux 
usually does not promote antibody binding 
to PF4.[2] Fondaparinux therefore carries an 
extremely low risk of HIT and may be used 
off-label to treat HIT in the acute phase of 
the disease.[18,21]
Fondaparinux administered subcutaneously 
has a bioavailability of 100%, predictable 
pharmacokinetics and a half-life of 17 hours. [1] 
The intravenous agents listed in Table 6 are 
alternatives to fondaparinux and can be 
considered if an intravenous anticoagulant 
with a shorter half-life is desired.[18,21] These 
intravenous agents are not widely available 
in SA, but may be accessed under the South 
African Health Products Regulatory Authority 
(SAHPRA) section 21 programme.
The American College of Chest Physi-
cians Evidence-Based Clinical Practice 
Guidelines for antithrombotic therapy and 
prevention of thrombosis[38] recommend 
fondaparinux (grade 2C recommendation) 
in pregnant patients with HIT, if danaparoid 
is not available.[38]
Direct oral anticoagulants
DOACs do not cross-react with anti-PF4/
heparin antibodies. Unlike warfarin, the 
DOACs have a fast onset of action, do not 
require routine monitoring and do not cause 
a decrease in protein C activity.[39] A recent 
systematic review and meta-analysis found 
that DOACs appear as safe and effective in 
the treatment of HIT as fondaparinux and 
other intravenous anticoagulants.[35]
The ASH 2018 guidelines[21] state that 
the DOACs (rivaroxaban, apixaban or 
dabigatran) are reasonable choices for the 
treatment of most patients with acute HIT 
and are suitable alternatives to warfarin 
following platelet count recovery (so-called 
subacute HIT). The majority of published 
clinical experience is with rivaroxaban, an 
anti-factor Xa inhibitor, which is currently the 
preferred DOAC in the setting of HIT. The 
DOACs are, however, not recommended 
If intermediate 4Ts score
 – obtain functional assay
Positive functional assay:
HIT conrmed (see the section 
on management of acute HIT)
Negative functional assay:
HIT unlikely (review 
anticoagulation as needed)
Patient exposed to heparin 
and HIT suspected
Determine 4Ts score
Low 4Ts score 
(0 - 3)
Intermediate 4Ts 
score (4 - 5)
High 4Ts 
score (6 - 8)
HIT testing not recommended – 
HIT unlikely
Can continue heparin therapy[18]





Negative for anti-PF4/heparin 
antibody using a highly 
sensitive assay – HIT unlikely
If high 4Ts score
– HIT likely
See the section on
 management of acute HIT
Fig. 4. Algorithm for the diagnosis and early management of heparin-induced thrombocytopenia.[2,18,21] 
(HIT = heparin-induced thrombocytopenia; PF4 = platelet factor 4; *For anti-PF4/heparin complex 
antibodies detected via immunoassay.)
Table 6. Intravenous anticoagulants recommended by the British Committee for Standards in Haematology and the 
American Society of Hematology for the treatment of acute heparin-induced thrombocytopenia[18,21]
Drug Drug class and administration Laboratory monitoring Cost per day*
Argatroban Direct thrombin inhibitor Dose-adjusted according to aPTT 
(1.5 - 3 times patient baseline)
ZAR6 730.73
Continuous IV infusion
Bivalirudin† Direct thrombin inhibitor Dose-adjusted according to aPTT 
(1.5 - 2.5 times patient baseline)
ZAR37 031.00
Continuous IV infusion
Danaparoid Heparinoid and indirect factor Xa inhibitor Anti-factor Xa with drug-specific 
calibrant (monitoring generally not 
required)
First day: ZAR23 116.60
Bolus followed by IV infusion Subsequent days: ZAR3 054.08
aPTT = activated partial thromboplastin time; IV = intravenous.
*Pricing for 2021, excluding VAT. Argatroban cost estimate is based on infusion rate of 1.5 µg/kg/min. Bivalirudin cost estimate is based on an infusion rate of 0.2 mg/kg/h. Danaparoid cost 
estimate is based on a total daily infusion of 8 500 U on day 1 followed by an infusion rate of 200 U/h on subsequent days. All calculations for a 70 kg individual.
†Recommended if intraoperative anticoagulation or cardiac surgery is required.[18]
848       September 2021, Vol. 111, No. 9
IN PRACTICE
in patients with HIT complicated by limb- or life-threatening 
thrombosis, when a parenteral anticoagulant is preferred. The 
contraindications to and indications for laboratory monitoring are 
the same as for non-HIT venous thromboembolism.[21]
Vitamin K antagonists
The use of a vitamin K antagonist (VKA) such as warfarin is not 
recommended in the acute phase of HIT, and should be withheld 
until the platelet count is >150 × 109/L.[18] Protein C, a vitamin 
K-dependent natural anticoagulant, has a short half-life and is 
rapidly depleted upon commencing VKA therapy. A decrease in 
protein C activity during the acute phase of HIT increases the risk of 
thrombosis, venous limb gangrene and skin necrosis.[2]
Warfarin is recommended as long-term anticoagulation therapy 
of HIT-associated thrombosis, but only after the platelet count 
has recovered to >150 × 109/L. Overlap with a non-heparin 
anticoagulant is recommended for at least 5 days and until the INR 
is within the therapeutic range. If the patient is on VKA therapy 
when HIT develops, VKA therapy should be stopped and the patient 
should receive parenteral vitamin K reversal after an alternative non-
heparin anticoagulant at an appropriate dose has been started.[18,39]
Platelet transfusion
Platelet transfusions in HIT may precipitate or worsen thrombosis. 
Platelet transfusions should be avoided unless the patient is 
actively bleeding.[18]
Surgery
The BCSH guidelines recommend postponing elective surgical 
procedures requiring anticoagulant therapy until the patient tests 
negative for anti-PF4/heparin antibodies. For patients with anti-
PF4/heparin antibodies in whom urgent surgery is required, non-
heparin anticoagulant therapy, if indicated, is recommended.[18]
Conclusions
HIT is an immune-mediated and potentially limb- and life- 
threatening complication of heparin therapy. Early diagnosis of HIT 
is essential to prevent complications and preserve life. The monitoring 
of platelet counts in certain at-risk groups on heparin therapy is 
important and ensures the early identification of possible HIT. The 
4Ts score is used to estimate the pretest probability of HIT, and guides 
laboratory testing and acute management. With the increased use of 
heparin during the COVID-19 pandemic and the associated risk of 
HIT, a high level of awareness is of paramount importance.
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